Ukuhunyushwa Kwezincwadi
Ucwaningo lwakamuva mayelana nokusetshenziswa kokuhlolwa kwe-pharmacogenetic (PGx) e-Italy, olushicilelwe kuyi-European Journal of Human Genetics, luchaza ngokuhlelekile ukusatshalaliswa kwezinsizakalo zokuhlola i-PGx, izinhlelo zokusebenza zobuchwepheshe, ukusetshenziswa kwemitholampilo, umehluko wesifunda, kanye nezinkinga zamanje e-Italy, olunikeza isisekelo esisekelwe ebufakazini sokukhuthazwa okujwayelekile kwe-pharmacogenetics e-Italy nakwamanye amazwe aseYurophu.
I. Isizinda kanye Nenhloso
Njengamanje, ukusetshenziswa kobuchwepheshe be-PGx e-Italy kuhlukene phakathi, ngaphandle kokuxhumana okuhlangene kuzwelonke kanye nendlela yokuqashelwa ngokubambisana. Ukuze kucaciswe isimo sokuhlolwa kwe-pharmacogenetic yezwe, ithimba locwaningo lenze inhlolovo yelabhorethri kazwelonke kusukela ngoJanuwari kuya ku-Okthoba 2025. Izinhloso eziyinhloko kwakuyilezi:
-Ukudweba imephu yokusatshalaliswa kanye nemephu yesevisi yamalebhu okuhlola i-pharmacogenetic e-Italy;
-Ukucacisa imisebenzi yokuhlola, amaphaneli ezakhi zofuzo, izindlela zobuchwepheshe, kanye nezindinganiso zokuhumusha;
-Ukwembula umehluko wesifunda kanye nezithiyo zokuqaliswa, ukuhlinzeka ngokusekelwa kwedatha yokwenziwa kwezindinganiso zikazwelonke.
II. Imiphumela Eyinhloko
Izici eziyisisekelo zamalebhu
Isici sesikhungo: Izikhungo ezingu-49 zihlanganyele, okungu-82% kuzo kwakuyizikhungo zomphakathi kanti u-18% kuphela kwakuyizikhungo ezizimele.
-Iminyango Eqhubayo: Iminyango yezofuzo zezokwelapha ibe nengxenye ephezulu kakhulu (39%), ilandelwe yiminyango yezifo zemitholampilo kanye neyamakhemikhali ezinto eziphilayo (18%), kanye neminyango yezokwelapha yezemithi (12%).
Ukuhlola izinhlelo zokusebenza kanye nezinhloso zezakhi zofuzo
Izimo zohlelo lokusebenza oluyinhloko:Ukuhlolwa kwe-PGx e-Italy kugxile kakhulu ku-oncology. Ama-94% (amalabhorethri angu-46) enze ukuhlolwa kwe-dihydropyrimidine dehydrogenase gene (DPYD) okuhlobene nokusetshenziswa kwe-fluoropyrimidine, kanye nama-84% (amalabhorethri angu-41) enze ukuhlolwa kwe-uridine diphosphate glucuronosyltransferase 1A1 gene (UGT1A1) okuhlobene nokusetshenziswa kwe-irinotecan.
Ezinye izivivinyo:Amalabhorethri enza izivivinyo zezakhi zofuzo ezihlobene ne-azathioprine, i-clopidogrel, i-warfarin, njll. (TPMT, CYP2C19, CYP2C9, VKORC1, njll.) ayengavamile kakhulu.
Ubuchwepheshe kanye nokunamathela okujwayelekile
Isu lokuhlola: Ukuhlolwa okungu-100% kwe-DPYD kanye no-97% kokuhlolwa kwe-UGT1A1 kwakuyizivivinyo zangaphambi kokwelashwa; i-CYP2C19 kanye ne-HLA B kwakuyizivivinyo ezingaphambi kokwelashwa; ukuhlolwa kwe-CYP2D6 kwakuvame ukusabela, kwenziwa ngemva kokwenzeka kwemiphumela emibi.
Izindlela zobuchwepheshe:I-PCR yesikhathi sangempela kwakuyindlela esetshenziswa kakhulu; i-NGS yayisetshenziswa kakhulu ukuthola i-HLA B gene; phakathi kwezikhungo ezibike imiphumela, ilabhorethri eyodwa kuphela esebenzise i-whole exome sequencing (WES).
Ukunamathela okujwayelekile:Ingxenye ephezulu kakhulu yamalebhu ilandele iziqondiso ze-Italian Society of Pharmacology/Italian Association of Medical Oncology (SIF/AIOM) kanye neziqondiso ze-Clinical Pharmacogenetics Implementation Consortium (CPIC)/Dutch Pharmacogenetics Working Group (DPWG).
Ukuchazwa kwemiphumela kanye nokubonisana
Ukusayina umbiko:Ama-65% emibiko yokuhlolwa asayinwe ochwepheshe bezofuzo, ama-31% ngochwepheshe bezifo zemitholampilo/i-biochemistry.
Ukuchazwa kwezokwelapha: Ama-90% amalabhorethri anikeze incazelo, ama-73% abonise ingozi yobuthi/ukungasebenzi kahle, kodwa ama-24% kuphela anikeze izincomo ezithile zokulinganisa imithi.
Ukubonisana nge-Pharmacy:Ama-29% kuphela amalabhorethri anikeza izinsizakalo zokubonisana ngemithi, futhi lezi cishe zazihlinzekwa yiminyango yemithi yezokwelapha kuphela - iminyango yezakhi zofuzo kanye ne-pathology yayihlinzeka ngezinsizakalo ezimbalwa kakhulu.
Imvume enolwazi:Ama-73% amalabhorethri asebenzise imigomo ethile noma ejwayelekile yemvume yolwazi lwe-pharmacogenetics.
Ukusatshalaliswa kwesifunda:Umsebenzi wokuhlola wawugxile kakhulu enyakatho ye-Italy. Phakathi kwama-laboratory anomthamo wokuhlola waminyaka yonke ongaphezu kuka-200, angu-23 ayesenyakatho, angu-4 enkabeni, kanye nangu-6 eningizimu naseziqhingini - ukusatshalaliswa kwezindawo zokuhlola okungalingani kakhulu esifundeni.
Ivolumu yokuhlola:Ama-69% amalabhorethri ayenomthamo wokuhlolwa waminyaka yonke ongaphezu kuka-200, angu-19% ayenawo angu-100 200.
Inqubomgomo yokubuyiselwa kwemali:Phakathi kwama-laboratory ahlolwe, ama-73% athole imbuyiselo ephelele evela ku-National Health System (NHS), imbuyiselo engaphelele engu-22%, kanye nama-4% angenayo imbuyiselo. Imithetho yokubuyiselwa kwemali yesifunda yayingaguquguquki. Njengamanje, i-Italy ayinayo ikhodi ethile yokukhokhisa/yokubuyiselwa kwemali yokuhlolwa kwe-pharmacogenetic, okubangela ukudideka okukhulu kokusetshenziswa kuzo zonke izifunda.
III. Ingxoxo kanye neziphetho ezibalulekile
Isikhundla esiphambili se-oncology– Ukuhlolwa kwe-DPYD kanye ne-UGT1A1 kusakazeke kabanzi ngenxa yokukhuthazwa kweziqondiso ezivela kwi-European Medicines Agency (EMA) kanye ne-Italian Medicines Agency (AIFA). Kodwa-ke, ukusetshenziswa kokuhlolwa kwe-pharmacogenetic emikhakheni engeyona i-oncology akwanele neze.
Ubuchwepheshe obungafani kanye nokuhumusha– Ayikho indinganiso ehlanganisiwe yamaphaneli okuhlola, ama-reagent, amathuluzi e-bioinformatics, noma izindlela zokuhumusha, okuholela ekuqhathanisekeni okubi kwemiphumela.
Ukubambisana okunganele kwemikhakha eminingi– Ukubandakanyeka okuphansi kochwepheshe bemithi kanye nokungatholakali ngokwanele kwezinsizakalo zokubonisana ngemithi yezokwelapha.
Ukungalingani okukhulu kwesifunda– Izinsiza zokuhlola i-PGx zigxile kakhulu ezikhungweni zezokwelapha ezisenyakatho, lapho izinsiza zimbalwa khona ezifundeni eziphakathi neziseningizimu – ukuntuleka kwezimali.
Ukusekelwa kwenqubomgomo okubuthakathaka– I-Italy ayinalo uhlaka lukazwelonke oluhlangene lokuhlolwa kwe-pharmacogenetic, okuholela ohlelweni oluphelele olungaphelele lokubuyiselwa kwemali, imithethonqubo, ukuqeqeshwa, njll.
Isifinyezo
Lolu cwaningo luwukuhlolwa kokuqala kuzwelonke kwesimo sokusetshenziswa kwe-pharmacogenetic e-Italy. Luqinisekisa ukuthi i-pharmacogenetics e-Italy isetshenziswe ekuqaleni emkhakheni we-oncology, kodwa iyonke ihlukene, ayilingani, ayilingani ngokwesifunda, futhi ayixhumene nemikhakha eminingi. Ngakho-ke, ukusungula uhlaka lokuhlanganisa lukazwelonke, ukuhlanganisa ubuchwepheshe kanye nezindinganiso zokuhumusha, kanye nokuthuthukisa izinqubomgomo kanye nokuqeqeshwa kuyizidingo zesikhathi esizayo ze-Italy ukuze kufezwe ukusetshenziswa okujwayelekile kwezokwelapha kokuhlolwa kwe-pharmacogenetic, okuhlinzeka ngereferensi ebalulekile kwamanye amazwe aseYurophu.
Ukuhlolwa Okukhulu Nokuncane'sIsixazululo Esigcwele Se-Pharmacogenomics Esizenzakalelayo
-Kulula: Ukulayisha isampula ngamashubhu okuqala, ukusebenzisa ukhiye owodwa, ukuzenzekela kwesampula kuya kumphumela, ukuhlanganiswa okungenamthungo ne-LIS/HIS.
-Okusheshayo: Imiphumela itholakala cishe ngehora elilodwa kuyo yonke inqubo, iqondisa ngqo izindlela zokwelapha ezenzelwe wena.
-Ukuzivumelanisa nezimo: Ngeplatifomu ye-HWTS AIO800, ukuhlolwa kwe-PGx akusanqunyelwe yimingcele yesayithi - eguquguqukayo futhi eguquguqukayo.
-Okuphelele: I-matrix yomkhiqizo ocebile ehlanganisa izifo zenhliziyo nemithambo yegazi, izifo zengqondo, ukwelashwa komdlavuza, ukubelethisa, izifo zabesifazane kanye nokuzala, kanye neminye imikhakha.
-Ukuhambisana:I-Full Automated Nucleic Acid Amplification Analyzer HWTS AIO800 kanye nezinhlelo ze-PCR zesikhathi sangempela ezivamile.
Isithasiselo:OkuhlobeneIzifoes, Izidakamizwa Ezihlobene, kanye Nezinhloso Zokuhlola Ufuzo Ezihambisanayo
Isikhathi sokuthunyelwe: Meyi-11-2026